| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
|
Join IQVIA Patient Suite experts Kevin Landells and Anthony Mikulaschek in this webinar as they explore the flexibility in choosing the right approach for integrating patient technology into your next trial. Whether you opt for an integrated solution or individual technology products, this webinar will guide you through the decision-making process to ensure you’re executing a patient technology strategy that fits your needs. 
|
|
Today’s Big NewsAug 28, 2024 |
|
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now! 
|
|
| By James Waldron The company has signed a deal worth over half a billion biobucks to partner up on two programs with NextRNA Therapeutics. |
|
|
|
By Nick Paul Taylor Neurocrine Biosciences has achieved its hoped-for profile in a phase 2 schizophrenia trial, delivering its targeted level of efficacy with a lower rate of gastrointestinal adverse events than Bristol Myers Squibb’s KarXT. But the biotech only saw efficacy at the lowest dose—the three higher doses all failed. |
By Fraiser Kansteiner Genentech will lay off 93 employees in South San Francisco starting in early October, the company confirmed through a Worker Adjustment and Retraining Notification alert sent to California. While it isn’t immediately clear what types of roles will be affected, local news outlet SFGate said the job cuts would impact scientists, engineers, managers and analysts, plus one executive. |
Sponsored by InMed Pharmaceuticals New disease-modifying drugs, biological pathways and blood-based biomarker tests are among the rapid changes shaping the Alzheimer’s disease landscape |
|
Luminex MAP profiles
Ultrasensitive Simoa
Olink Target 48 Cytokine 
|
|
By Gabrielle Masson Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases. |
Sponsored by Bio-Rad Laboratories In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani delves into the challenges and solutions of quantifying HEK293 DNA in biotherapeutics, a field revolutionizing healthcare for over 350 million patients worldwide. |
By Nick Paul Taylor UCLA has received a $120 million commitment to support the recently established California Institute for Immunology and Immunotherapy, positioning the university to establish research entities in Los Angeles focused on vaccine development and the microbiome. |
By Angus Liu Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. |
By Zoey Becker Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage. |
By Darren Incorvaia Curi Bio is on the move. The Seattle-based companu has signed a seven-year lease for a roomy, 13,942-square-foot space, with plans to move in by early 2025. |
By Kevin Dunleavy The Delaware Supreme Court has upheld a GSK appeal, deciding to review the state’s Superior Court decision to allow expert testimony that would support 75,000 personal injury Zantac lawsuits that have been consolidated in the state. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry. |
|
|---|
|
|
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
